Substance / Medication

Bismuth subnitrate

Overview

Active Ingredient
bismuth subnitrate
RxNorm CUI
19477

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Consequences of Shigella infection in young children: a systematic review.
Libby Tanya E, Delawalla Miranda L M, Al-Shimari Fatima et al. · Int J Infect Dis · 2023
PMID: 36736579Meta-AnalysisFull text (PMC)
Antimicrobial resistance in sexually transmittedin men who have sex with men: A systematic review.
O'Flanagan Holly, Siddiq Mohammed, Llewellyn Carrie et al. · Int J STD AIDS · 2023
PMID: 36786731Meta-Analysis
The increasing antimicrobial resistance ofspecies among Iranian pediatrics: a systematic review and meta-analysis.
Baharvand Amirhossein, Molaeipour Leila, Alesaeidi Sogol et al. · Pathog Glob Health · 2023
PMID: 36794800Meta-AnalysisFull text (PMC)
Bismuth Subnitrate-Catalyzed Markovnikov-Type Alkyne Hydrations under Batch and Continuous Flow Conditions.
Szécsényi Zsanett, Fülöp Ferenc, Ötvös Sándor B · Molecules · 2021
PMID: 34066109OtherFull text (PMC)
Cellular Response of Neutrophils to Bismuth Subnitrate and Micronized Keratin Products In Vitro.
Notcovich Shirli, Williamson Norman B, Yapura Jimena et al. · Vet Sci · 2020
PMID: 32640682OtherFull text (PMC)
The efficiacy of bismuth subnitrate against genotoxicity and oxidative stress induced by aluminum sulphate.
Turkez Hasan, Geyikoglu Fatime · Toxicol Ind Health · 2011
PMID: 20823050Other
Effect of bismuth subnitrate on in vitro growth of major mastitis pathogens.
Notcovich S, Williamson N B, Flint S et al. · J Dairy Sci · 2020
PMID: 32475664Preclinical
Citrate enhances the protective effect of orally administered bismuth subnitrate against the nephrotoxicity of cis-diamminedichloroplatinum.
Kondo Yukihiro, Himeno Seiichiro, Satoh Masahiko et al. · Cancer Chemother Pharmacol · 2004
PMID: 14530870Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Bismuth subnitrate (substance)
SNOMED CT
391852006
UMLS CUI
C0053791
RxNorm CUI
19477

Clinical Data

This intervention maps to 4 entities in the Ltrl knowledge graph.

4
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.